ArticleJournal of managed care & specialty pharmacy2026
Predicting self-administered biologic nonadherence in Medicare fee-for-service beneficiaries with inflammatory bowel disease using machine learning models.
Article in Journal of managed care & specialty pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonadherence to self-administered biologic therapies increases risk for disease flares and adverse outcomes in inflammatory bowel disease (IBD).
objectiveTo use machine learning and Medicare fee-for-service claims to create models predictive of medication nonadherence.
methodsThis study included Medicare fee-for-service beneficiaries with at least 2 IBD claims separated by 30 days between 2017 and 2021 and analyzed claims data from 2021. Beneficiaries with missing data or fewer than 3 self-administered biologic dispenses (adalimumab, certolizumab, golimumab, ustekinumab) on different dates in 2021 were excluded. Beneficiary-level nonadherence was defined as a proportion of days covered less than 0.8, and dispense-level nonadherence as dispenses occurring more than 5 days after previous supply elapsed. Sixteen machine learning models were trained, and model performance was evaluated based on area under the receiver operating characteristic curve (AUC) scores, accuracy, F1 score, positive and negative predictive value (P/NPV), sensitivity, and specificity.
resultsA total of 10,160 beneficiaries met inclusion and exclusion criteria. Subsequently, 64,197 dispense transactions were observed, with 8,547 (13.3%) considered nonadherent. Prior nonadherence was strongly associated with current dispense nonadherence (odds ratio, 2.65; 95% CI, 2.53-2.78). The random forest dispense-level model had fair predictive performance (AUC 0.739, accuracy 85.4%, sensitivity 17.7%, specificity 95.8%, PPV 39%, NPV 88.3%, F1 score 0.243). The bagging dispense-level model performed comparably with higher sensitivity (AUC 0.714, accuracy 74.9%, sensitivity 51%, specificity 78.6%, PPV 26.8%, NPV 91.3%, F1 score 0.351).
conclusionsMachine learning models trained on Medicare fee-for-service claims data had fair predictive performance identifying nonadherent dispenses. The bagging model, which minimizes false negatives, may be most appropriate for future clinical decision support tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.